(lp0
S'Trovagene and Nerviano Announce License Agreement for therapeutic candidate ... PR Newswire  - Mar 15, 2017 SAN DIEGO and NERVIANO, Italy, March 15, 2017 /PRNewswire/ -- Trovagene, Inc. , a precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.Trovagene nabs rights to leukemia candidate from Nerviano Medical - Seeking AlphaWhy TrovaGene Inc  Reported Restructuring Plan? - StockNewsUnion'
p1
aS'Earnings Reaction History: TrovaGene, Inc., 75.0% Follow-Through Indicator, 7 ... Nasdaq - Mar 15, 2017 TrovaGene, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement.'
p2
aS'Trovagene and Boreal Genomics Announce Strategic Partnership PR Newswire  - Nov 30, 2016 SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today announced it has entered into a long-term Supply and Distribution Agreement with Boreal Genomics,&nbsp;...'
p3
aS'Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and ... PR Newswire  - Mar 1, 2017 SAN DIEGO, March 1, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will report financial results for the fourth quarter and year ended December 31, 2016&nbsp;...'
p4
aS'Trovagene Announces Broadening Network of Commercial Distributors PR Newswire  - Jan 12, 2017 SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for&nbsp;...Trovagene inks seven deals for commercialization of liquid biopsy tests ex-US - Seeking Alpha'
p5
aS'Trovagene announces a reorganization to accelerate global distribution of ... PR Newswire  - Dec 13, 2016 SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will increase its focus on the global distribution of kits and systems to clinical&nbsp;...Trovagene to Focus More on Liquid Biopsy Testing Market - Yahoo FinanceTrovagene Axes 20 Staffers, Refocuses on Distributing Kits, Systems - Genetic Engineering & Biotechnology News'
p6
aS'Trovagene to Attend the 29th Annual ROTH Conference PR Newswire  - Feb 28, 2017 SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March 12-15, 2017, at the Ritz Carlton Laguna&nbsp;...'
p7
aS"Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments PR Newswire  - Nov 9, 2016 SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today reported its financial results and accomplishments for the third quarter ended September 30, 2016.TrovaGene's  CEO Bill Welch on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha"
p8
aS"What Type of Consensus Opinions Analysts hold about TrovaGene, Inc.'s (TROV ... Hot Stocks Point - 15 hours ago TrovaGene, Inc. , a part of Healthcare sector and belongs to Medical Laboratories &amp; Research industry; ended its day with no change 0.00% and finalized at the price of $1.30.Maxim Group Downgrades TrovaGene Inc  to Hold - The Cerbat GemErratic Trading Showing Unusual Volume in Shares of TrovaGene, Inc.  - Melville Review"
p9
aS"Analyst's Proposition on TrovaGene, Inc. , The Goldfield Corporation  The USA Commerce - Mar 17, 2017 Presently TrovaGene, Inc.  stock have an ABR of 1.67. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.Time To Get Cautious?  TrovaGene, Inc. , The Goldfield Corporation  - USA Commerce Daily"
p10
a.